Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier

Gharbavi, Mahmoud; Amani, Jafar; Kheiri-Manjili, Hamidreza; Danafar, Hossein; Sharafi, Ali

doi:10.1155/2018/6847971

Cited by 169 publications

(143 citation statements)

References 76 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…Niosomes have the ability to entrap lipophilic or hydrophilic drugs and are able to deliver the drug molecules at target site in a sustained and/or controlled manner [56,57]. Niosomes have been reported to modify drugs organ distribution and metabolic stability [58]. It has been shown that surface modification of the niosomes promotes the target specificity for the cancer drug delivery system.…”

Section: Niosomesmentioning

confidence: 99%

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

Although the global prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing, effective delivery of drug molecules in therapeutic quantities to the central nervous system (CNS) is still lacking. The blood brain barrier (BBB) is the major obstacle for the entry of drugs into the brain, as it comprises a tight layer of endothelial cells surrounded by astrocyte foot processes that limit drugs' entry. In recent times, intranasal drug delivery has emerged as a reliable method to bypass the BBB and treat neurological diseases. The intranasal route for drug delivery to the brain with both solution and particulate formulations has been demonstrated repeatedly in preclinical models, including in human trials. The key features determining the efficacy of drug delivery via the intranasal route include delivery to the olfactory area of the nares, a longer retention time at the nasal mucosal surface, enhanced penetration of the drugs through the nasal epithelia, and reduced drug metabolism in the nasal cavity. This review describes important neurological disorders, challenges in drug delivery to the disordered CNS, and new nasal delivery techniques designed to overcome these challenges and facilitate more efficient and targeted drug delivery. The potential for treatment possibilities with intranasal transfer of drugs will increase with the development of more effective formulations and delivery devices. Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neurodegenerative disease, leading to the development of bradykinesia and tremors of cardinal motor functions ( Figure 2) [3]. PD models specifically show a decrease in dopamine transporters, which are responsible for dopamine uptake by dopaminergic neurons and progression of neuronal communications. Reduced Figure 1. Schematic demonstrating various transport systems that shuttle molecules across the BBB. Very small amount of water-soluble compounds cross through the tight junctions (paracellular), whereas lipid-soluble agents traverse via the transcellular lipophilic pathway. Selective transport systems exist for glucose, amino acids, nucleosides, and other substances, in addition to specific receptor-mediated endocytosis for certain proteins such as insulin and transferrin. (AZT = azathioprine). List of CNS Diseases Parkinson's Disease (PD)PD, occurring primarily in the substantia nigra, is the second-most common neuro...

show abstract

Section: Niosomesmentioning

confidence: 99%

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The specific color of MB is due to the strong absorption band in the 550-700 nm regions with maximum molar absorptivity of 85,000 M−1 cm−1 at 664nm [11]. Methylene blue is a molecule having vital roles in microbiology and pharmacology; moreover it is used to stain living organisms considered as a Photosensitizer for photodynamic therapy [12][13][14][15][16]. Niosomes (the nonionic surfactant vesicles) can improve the solubility as well as the stability of pharmaceutical molecules since niosomes can act as drug reservoirs, can be a carrier for hydrophilic and hydrophobic drugs and has the adjusting effect on drug release rate [17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

“…In particular, topical application of niosomes has an increasing effect on the residence time of drugs in the stratum corneum and epidermis. Moreover, non-ionic surfactants normally show favorable dermatological properties [16]. Skin is a vital organ offering an appropriate site for administration of many drugs.…”

Section: Introductionmentioning

confidence: 99%

Formulation and clinical evaluation of niosomal methylene blue for successful treatment of acne

El-Mahdy

Mohamed

Saddik

et al. 2020

Journal of advanced Biomedical and Pharmaceutical Sciences

View full text Add to dashboard Cite

Photodynamic therapy (PDT) can be defined as the administration of a nontoxic drug or dye known as Photosensitizer (PS) either systemically, locally, or topically to a patient bearing a lesion. Methylene blue considered as a photosensitizer for photodynamic therapy. Current topical and oral therapies for acne vulgaris have limited efficacy, especially in moderate to severe cases, In view of this, the aim of our study was to use methylene blue in the form of niosomal hydrogel for photodynamic treatment of acne. To reach this objective we studied the following aspects; formulation of MB blue in different niosomal preparation, characterization of methylene blue niosomes, Span 60 transition temperatures, In vitro release study, kinetic analysis of the release data, factors affecting the encapsulation of methylene blue in niosomes via effect of: amount of drug, cholesterol: span 60 ratios, and stabilizers. The results revealed that, niosomes were successfully produced by reversed phase evaporation technique using different ratio of cholesterol: span 60.The most favorable amount of MB could be used in niosomal preparation was 1000µg. The best fit kinetic favored Higuchi diffusion mechanism. The incorporation of MB niosomes in HPMC 3% gel resulted in feasible release rate of MB. The data obtained served as the basis to reach a secondary objective which is clinical evaluation of selected niosomal gel of methylene blue for photodynamic treatment of acne which showed higher significant improvement in inflammation when compared with IPL treatment.

show abstract

“…Niosomes are novel drug delivery system, in which the medicament is encapsulated in a vesicle. The vesicle is composed of a bilayer of non ionic surfactant and cholesterol (Gharbavi et al, 2018). A bioadhesive material (polymer) coated niosomal formulation of anti-infective agent was purposed to show a longer retention time on eye and subsequent reduction in dosing frequency.…”

Section: Introductionmentioning

confidence: 99%

Molecular Investigation of hemolytic phospholipase C Encoding Genes in Clinical Isolates of Pseudomonas aeruginosa

Saleh

Naher

Al-Saadi

2018

Int. J. Res. Ph. Sci.

View full text Add to dashboard Cite

Corneal ulcer is an open sore or epithelial defect with an in lammation of the cornea of the eye. Most of the corneal ulcers are caused by bacterial infections and are common in people who wear contact lenses. Moxi loxacin eye drops are frequently used for the treatment of infectious ulcers. However such formulations have a major drawback, that is the short duration of action and usually, require 4-6 times instillation daily. A bioadhesive polymer coated niosomal formulation of moxi loxacin was purposed to show a longer retention time on eyes and subsequent reduction in dosing frequency. Niosomes were prepared by solvent injection method using cholesterol and span 60. The coating of the niosomes was done using Carbopol 934or HPMC as bioadhesive polymer. The mean particle size of bioadhesive niosomes found to be below 200nm. Optimization of the coating was based on in vitro diffusion studies, ex vivo transcorneal permeation studies and bioadhesion studies. The retention time of the formulation was determined by in vitro and ex vivo bioadhesion testing. The antimicrobial assay con irmed the potency of the formulation against the gram-negative organism. The current study revealed that bioadhesive niosomal formulations have longer corneal retention time and have sustained drug release for a period of 24 hours.

show abstract

Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier

Cited by 169 publications

References 76 publications

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders

Formulation and clinical evaluation of niosomal methylene blue for successful treatment of acne

Molecular Investigation of hemolytic phospholipase C Encoding Genes in Clinical Isolates of Pseudomonas aeruginosa

Contact Info

Product

Resources

About